The Latest Breaking News from PFE

Pfizer (PFE) is spending its COVID-19 cash flows on meaningful growth avenues. However, given a recent downgrade, should value investors still be excited about this stock? Let’s look at the trends of its financial metrics to get an idea….

Rivian’s strong sales results drove the unusual options activity in Friday trading. For those who aren’t enamored with the electric vehicle manufacturer’s business, there are, pardon the pun, other options.

With the growing prevalence of chronic conditions, an aging population, widespread adoption of digital technologies, and several R&D efforts, the pharmaceutical industry is poised for exponential growth and expansion. So, let’s compare leading pharma stocks AbbVie (ABBV) and Pfizer (PFE) to identify which is a better investment now. Keep reading….

The pharma sector is poised to witness significant growth due to the widespread adoption of generic medicines and emerging technologies. Therefore, fundamentally strong pharma stocks Pfizer (PFE), Sanofi (SNY), and Spero Therapeutics (SPRO) might be solid buys. Read on.

Despite a slowdown of Covid-19 vaccine sales in the last reported quarter, biopharmaceutical giant Pfizer (PFE) is positioned to deliver robust growth this year and beyond, thanks to the strength of its in-line products and expected near-term launches and revenue distribution from the recent acquisition. So, let’s find out if…

The pharmaceutical industry is known for its resilience during challenging economic times, primarily due to the inelastic demand for essential medicines. As the specter of a potential recession hangs over the market, let us analyze two leading players in the sector, Pfizer (PFE) and SNDL (SNDL), to find the better…

Pfizer (PFE) continues to make significant strides in the pharmaceutical industry, given its recent acquisition and drug approvals. Is the stock a buy, sell, or hold now? Keep reading to find out….

Councillor accuses developer of 'jumping the gun'

The biotech industry is growing thanks to breakthrough advancements and government initiatives. Furthermore, during market downturns, the biotech sector is more defensive than others. So, fundamentally sound biotech stocks Pfizer (PFE) and AstraZeneca (AZN) could be worth buying. Read on.

Recent banking turmoil and rising interest rates have weighed heavily on investors’ sentiment lately. However, weak economic data signaling slowing growth could result in relatively easy monetary policies in the second half of 2023. Given the macroeconomic backdrop, investors could consider adding fundamentally sound low P/E stocks Pfizer (PFE), Chevron…

Popular brokerage company Robinhood (HOOD) attracts millennials and Generation Z traders by offering zero-commission financial services. While not all stocks traded on this platform possess fundamental strength, investors could consider buying fundamentally sound Robinhood stocks Visa (V) and Pfizer (PFE) and holding them for the long term. Keep reading….